{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:23:38Z","timestamp":1750533818917},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","oralmaxsurgery.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.coms.2015.07.002","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T22:07:16Z","timestamp":1445897236000},"page":"561-566","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Bhoomi","family":"Mehrotra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coms.2015.07.002_bib1","unstructured":"Pamidronate Package Insert. March 2010. Available at: http:\/\/fresenius-kabi.ca\/wp-content\/uploads\/2015\/01\/EN_Web_Insert_Pamid_NL.pdf."},{"issue":"1","key":"10.1016\/j.coms.2015.07.002_bib2","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.1992.10.1.134","article-title":"Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia","volume":"10","author":"Gucalp","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.07.002_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2015.07.002_bib4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2015.07.002_bib5","unstructured":"Zoledronic Acid Package Insert. January 2015. Available at: https:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/Zometa.pdf."},{"issue":"2","key":"10.1016\/j.coms.2015.07.002_bib6","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.07.002_bib7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1056\/NEJMoa0806285","article-title":"Endocrine therapy plus zoledronic acid in premenopausal breast cancer","volume":"360","author":"Gnant","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2015.07.002_bib8","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coms.2015.07.002_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.503","article-title":"Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG\/Alliance\/ECOG-ACRIN\/NCIC Clinical trials group\/NRG Oncology Study S0307","volume":"33","author":"Gralow","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.coms.2015.07.002_bib10","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.coms.2015.07.002_bib11","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.07.002_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.9501","article-title":"CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer","volume":"33","author":"Himelstein","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.07.002_bib13","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.coms.2015.07.002_bib14","unstructured":"Denosumab Package Insert. June 2015. Available at: http:\/\/pi.amgen.com\/united_states\/xgeva\/xgeva_pi.pdf."},{"issue":"35","key":"10.1016\/j.coms.2015.07.002_bib15","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.coms.2015.07.002_bib16","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.coms.2015.07.002_bib17","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"30","key":"10.1016\/j.coms.2015.07.002_bib18","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Oral and Maxillofacial Surgery Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369915000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1042369915000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T20:29:32Z","timestamp":1567283372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1042369915000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S1042369915000709"],"URL":"https:\/\/doi.org\/10.1016\/j.coms.2015.07.002","relation":{},"ISSN":["1042-3699"],"issn-type":[{"value":"1042-3699","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiresorptive Therapies for the Treatment of Malignant Osteolytic Bone Disease","name":"articletitle","label":"Article Title"},{"value":"Oral and Maxillofacial Surgery Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coms.2015.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}